Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells
- 9 January 2009
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 378 (2), 279-284
- https://doi.org/10.1016/j.bbrc.2008.11.033
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinomaHepatology, 2008
- The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinomaLaboratory Investigation, 2005
- Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt SignalingCancer Research, 2005
- Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular CarcinomaCancer Research, 2004
- Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movementsThe Journal of cell biology, 2003
- Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signalingInternational Journal of Cancer, 2002
- Glypicans: proteoglycans with a surpriseJCI Insight, 2001
- OCI-5/GPC3, a Glypican Encoded by a Gene That Is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line–specific MannerThe Journal of cell biology, 1998
- Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndromeNature Genetics, 1996
- Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.The Journal of Experimental Medicine, 1978